TCT 2019 – Abbott's aortic valve disappoints
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
TCT 2019 – Orchestra data could lead to a duet
Data on the company’s pacemaker-neurostimulator combo are probably good enough to permit further development – but first the company wants to hook a partner.
Abbott’s Tendyne valve shows early promise in calcification
Feasibility trial success could mean a new therapy, but not for a few years yet.
Upcoming events – Obseva's first fibroid foray and Newron's test in Retts
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
ESC 2019 – Amarin hopes for guideline boost despite regulatory delay
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
Vantage ESC 2019 roundup
A collection of all of Vantage's coverage from the 2019 European Society of Cardiology meeting.
ESC 2019 – Carmat is stout-hearted in the face of a challenging schedule
Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.
ESC 2019 – Medicines Company impresses with inclisiran
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.
ESC 2019 – Astra’s latest Brilinta hopes bleed out on full Themis data
An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.